We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial
News

Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial

Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial
News

Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Peregrine Pharmaceuticals, Inc. has announced the initiation of an investigator-sponsored trial (IST) for patients with castration-resistant prostate cancer (CRPC). Peregrine's fourth IST, this Phase I/II trial will treat up to 31 second-line CRPC patients with Peregrine's investigational monoclonal antibody bavituximab in combination with the chemotherapeutic agent cabazitaxel.

"Once prostate cancer patients have failed treatment with docetaxel-based chemotherapy, options are unfortunately limited," said Michael Lilly, M.D., principal investigator and professor of clinical medicine, Division of Hematology-Oncology at The University of California, Irvine.

Lilly continued, "As the first approved agent for second-line CRPC, cabazitaxel provides modest survival benefits, but there remains significant room for improvement in the treatment of this patient population. We look forward to evaluating whether the combination of bavituximab and cabazitaxel can extend progression-free survival in these patients."

In multiple clinical trials, bavituximab combined with taxane-based chemotherapies has demonstrated promising signs of anti-tumor activity and a positive safety profile. In a preclinical model of CRPC, a bavituximab-like antibody combined with taxane-based chemotherapy yielded potent anti-tumor effects, reducing primary tumor burden by 95% and completely inhibited metastatic development.

Bavituximab is also being evaluated in randomized Phase II trials in non-small cell lung cancer (NSCLC), pancreatic cancer, and hepatitis C virus (HCV) infection, as well as multiple ISTs in different oncology indications.

Advertisement